Long-term reversal of chronic anemia using a hypoxia-regulated erythropoietin gene therapy

被引:75
作者
Binley, K
Askham, Z
Iqball, S
Spearman, H
Martin, L
de Alwis, M
Thrasher, AJ
Ali, RR
Maxwell, PH
Kingsman, S
Naylor, S
机构
[1] Oxford Biomedica UK Ltd, Medawar Ctr, Oxford OX4 4GA, England
[2] UCL, Inst Ophthalmol, Dept Mol Genet, London, England
[3] Univ London Imperial Coll Sci Technol & Med, Renal Sect, London, England
关键词
D O I
10.1182/blood-2002-02-0605
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Anemia Is a common clinical problem, and there is much interest In Its role In promoting left ventricular hypertrophy through increasing cardiac workload. Normally, red blood cell production is adjusted through the regulation of erythropoletin (Epo) production by the kidney. One Important cause of anemia Is relative deficiency of Epo, which occurs in most types of renal disease. Clinically, this can be corrected by supplementation with recombinant Epic. Here we describe an oxygen-regulated gene therapy approach to treating homozygous erythropoletin-SV40 T antigen (Epo-TAg(h)) mice with relative erythropoletin deficiency. We used vectors in which murine Epo expression was directed by an Oxford Blomedica hypoxia response element (OBHRE) or a constitutive cytomegalovirus (CMV) promoter. Both corrected anemia, but CMV-Epo-treated mice acquired fatal polycythemia. In contrast, OBHRE-Epo corrected the hematocrit level in anemic mice to a normal physiologic level that stabilized without resulting In polycythemia. Importantly, the OBHRE-Epo vector had no significant effect on the hematocrit of control mice. Homozygous Epo-TAgh mice display cardiac hypertrophy, a common adaptive response In patients with chronic anemia. In the OBHRE-Epo-treated Epo-TAg(h) mice, we observed a significant reversal of cardiac hypertrophy. We conclude that the OBHRE promoter gives rise to physiologically regulated Epo secretion such that the hematocrit level is corrected to healthy In anemic Epo-TAgh mice. This establishes that a hypoxia regulatory mechanism similar to the natural mechanism can be achieved, and it makes EPO gene therapy more attractive and safer in clinical settings. We envisage that this control system will allow regulated delivery of therapeutic gene products in other Ischemic settings. (C) 2002 by The American Society of Hematology.
引用
收藏
页码:2406 / 2413
页数:8
相关论文
共 40 条
  • [1] [Anonymous], 1989, Lancet, V2, P20
  • [2] COLOCALIZATION OF ERYTHROPOIETIN MESSENGER-RNA AND ECTO-5'-NUCLEOTIDASE IMMUNOREACTIVITY IN PERITUBULAR CELLS OF RAT RENAL-CORTEX INDICATES THAT FIBROBLASTS PRODUCE ERYTHROPOIETIN
    BACHMANN, S
    LEHIR, M
    ECKARDT, KU
    [J]. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1993, 41 (03) : 335 - 341
  • [3] Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo
    Bartholomew, A
    Patil, S
    Mackay, A
    Nelson, M
    Buyaner, D
    Hardy, W
    Mosca, J
    Sturgeon, C
    Siatskas, M
    Mahmud, N
    Ferrer, K
    Deans, R
    Moseley, A
    Hoffman, R
    Devine, SM
    [J]. HUMAN GENE THERAPY, 2001, 12 (12) : 1527 - 1541
  • [4] Transfer of the feline erythropoietin gene to cats using a recombinant adeno-associated virus vector
    Beall, CJ
    Phipps, AJ
    Mathes, LE
    Stromberg, P
    Johnson, PR
    [J]. GENE THERAPY, 2000, 7 (06) : 534 - 539
  • [5] An adenoviral vector regulated by hypoxia for the treatment of ischaemic disease and cancer
    Binley, K
    Iqball, S
    Kingsman, A
    Kingsman, S
    Naylor, S
    [J]. GENE THERAPY, 1999, 6 (10) : 1721 - 1727
  • [6] Characterization of physiologically regulated vectors for the treatment of ischemic disease
    Boast, K
    Binley, K
    Iqball, S
    Price, T
    Spearman, H
    Kingsman, S
    Kingsman, A
    Naylor, S
    [J]. HUMAN GENE THERAPY, 1999, 10 (13) : 2197 - 2208
  • [7] Improvement of erythropoiesis in β-thalassemic mice by continuous erythropoietin delivery from muscle
    Bohl, D
    Bosch, A
    Cardona, A
    Salvetti, A
    Heard, JM
    [J]. BLOOD, 2000, 95 (09) : 2793 - 2798
  • [8] Long-term control of erythropoietin secretion by doxycycline in mice transplanted with engineered primary myoblasts
    Bohl, D
    Naffakh, N
    Heard, JM
    [J]. NATURE MEDICINE, 1997, 3 (03) : 299 - 305
  • [9] Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector
    Bohl, D
    Salvetti, A
    Moullier, P
    Heard, JM
    [J]. BLOOD, 1998, 92 (05) : 1512 - 1517
  • [10] Biological basis of anemia
    Bron, D
    Meuleman, N
    Mascaux, C
    [J]. SEMINARS IN ONCOLOGY, 2001, 28 (02) : 1 - 6